Guangdong Xiangxue Precision Medical Technology Co., Ltd. Report issue

Academic/Hospital Phase 1 Phase 2

Organization Overview

First Clinical Trial
2020
NCT04318964
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Guangdong Xiangxue Precision Medical Technology Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

genetically engineered ny-eso-1-specific t lymphocytes (1 trial)

Drugs in Phase 1 Trials (1)

taest16001 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sarcoma (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2